Indian researchers have in collaboration with the international research community developed the Rotavac-vaccine. The price of Rotavac is many times less than other available rotavirus-vaccines, and will therefore be available for millions of children in low and middle income countries.
500 000 deaths annually
Rotavirus causes dehydration and severe diarrhea and spreads through contaminated hands and surfaces and is rampant in Asia and Africa. Rotavirus infections are the most severe and lethal cause of childhood diarrhea, responsible for approximately 100,000 deaths of small children in India each year, and 500,000 globally.
The GLOBVAC-program of the Research Council of Norway has contributed financially to the vaccination research project. GLOBVAC’s contribution is 4 million dollars (of the total 29 million dollars) to the international nonprofit organization PATH.
Rotavac is produced by Hyderabad-based Bharat Biotech, in India.
The vaccine trial started in March 2011, and included 6799 children in three Indian regions. The trial was completed in September 2014, and indicates that Rotavac reduces the occurrence of rotavirus-diarrhea by 56 % the first year after birth, and the protection continues into the second year.
Rotavac was officially introduced in India’s routine immunization schedule on 26 March 2016.